Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. DiPersio on Investigational Targeted Cellular Therapies in AML

October 10th 2019

John F. DiPersio, MD, PhD, discusses the current state of CAR T-cell therapy, dual affinity re-targeting, bi-specific T-cell engagers, and antibody-drug conjugates for acute myeloid leukemia treatment.

Spreading Newfound Treatment Strategies in Hematologic Malignancies in Seattle

October 9th 2019

We traveled to Seattle, Washington, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Seattle Cancer Care Alliance faculty.

FDA Awards Research Grants for 12 Rare Diseases, Including GIST, AML, and Brain Tumors

October 9th 2019

The FDA has awarded 12 new research grants that together total more than $15 million, to enhance the development of medical products for patients with rare diseases, including acute myeloid leukemia and gastrointestinal stromal tumor, among others.

Making Headway in Hematologic Cancer Research at UCLA

October 8th 2019

Leading oncology experts at the University of California, Los Angeles share the pivotal research being conducted at their institution.

Dr. Perl on Choosing the Optimal Therapy in AML

October 2nd 2019

Alexander E. Perl, MD, MS, discusses how to assess what therapy is best for patients with acute myeloid leukemia.

Research Findings Point to Clinical Importance of Clonal Hematopoiesis

October 2nd 2019

Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.

Dr. Timmerman on Recent Developments in Hodgkin Lymphoma Treatment

September 28th 2019

John M. Timmerman, MD, discusses recent developments made in the treatment of patients with Hodgkin lymphoma.

Targeted Agents Lead Treatment Advances in T-Cell Lymphoma

September 26th 2019

Jasmine M. Zain, MD, discusses the phase III ECHELON-2 trial and the ongoing work being done in peripheral T-cell lymphoma and other T-cell lymphomas.

Dr. Tabbara on the Expansion of Treatment Options for AML

September 26th 2019

Imad Tabbara, MD, discusses the expansion of treatment options for patients with acute myeloid leukemia.

Blinatumomab Studies Stopped Early for Clinical Benefit in Pediatric Relapsed ALL

September 25th 2019

Two clinical trials evaluating blinatumomab compared with chemotherapy in pediatric patients with acute lymphoblastic leukemia were stopped early due to treatment benefit with the bispecific T-cell engager.

Lymphoma Expert Weighs Treatment Advances in the Context of Toxicity

September 25th 2019

John M. Timmerman, MD, discusses the research being conducted across the spectrum of Hodgkin and non-Hodgkin lymphoma.

Amplifying Responses With ADCs and Checkpoint Inhibitors in Hodgkin Lymphoma

September 25th 2019

Matthew G. Mei, MD, discusses current considerations in the frontline management of advanced-stage Hodgkin lymphoma as well as ongoing investigations with checkpoint inhibitors and cellular-based therapy.

Treatment Options Are Expanding for Benign Hematologic Disorders

September 24th 2019

Kanwarpal S. Kahlon, MD, discusses current treatment options for patients with aplastic anemia, immune thrombocytopenic purpura, and thrombotic thrombocytopenic purpura, as well as future research for the field.

Brentuximab Vedotin and Nivolumab Explored in Frontline Hodgkin Lymphoma Regimen

September 23rd 2019

The addition of the antibody-drug conjugate brentuximab vedotin and the PD-1 inhibitor nivolumab to chemotherapy in patients with stage I/II Hodgkin lymphoma is under investigation in an ongoing phase II trial (NCT03233347).

Dr. Shah on the Use of Tisagenlecleucel in Pediatric ALL

September 21st 2019

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Gilteritinib Approaches EU Approval for FLT3-Mutant AML

September 21st 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of gilteritinib as a single agent for the treatment of adult patients with relapsed/refractory acute myeloid leukemia who have FLT3 mutations.

AML Research Focus Adapting to Address Heterogeneity

September 20th 2019

Gary J. Schiller, MD, discusses therapeutic advances, the importance of genomic testing, and other agents in the pipeline for acute myeloid leukemia.

Elements of Treatment Discontinuation Weighed in CML

September 19th 2019

Christopher S. Seet, MD, PhD, discusses elements of treatment discontinuation in chronic myeloid leukemia.

Dr. Seet on Aspects of Treatment Discontinuation in CML

September 18th 2019

Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).

Ruxolitinib Combo Regimens Emerging in Myelofibrosis

September 17th 2019

Although several newer JAK inhibitors are being investigated, such as pacritinib, momelotinib, and the recently FDA-approved fedratinib, most combinations are being explored in combination with ruxolitinib.